Home/Filings/4/0001567619-20-021613
4//SEC Filing

Whitehead Warren 4

Accession 0001567619-20-021613

CIK 0000882361other

Filed

Dec 27, 7:00 PM ET

Accepted

Dec 28, 6:00 PM ET

Size

11.6 KB

Accession

0001567619-20-021613

Insider Transaction Report

Form 4
Period: 2020-12-22
Transactions
  • Exercise/Conversion

    Common Shares

    2020-12-22$2.01/sh+20,000$40,20060,000 total
  • Sale

    Common Shares

    2020-12-22$4.11/sh10,000$41,10040,000 total
  • Exercise/Conversion

    Director Stock Option (Right to Buy)

    2020-12-2220,00020,000 total
    Exercise: $2.01From: 2019-01-02Exp: 2029-01-02Common Shares (40,000 underlying)
  • Sale

    Common Shares

    2020-12-22$4.01/sh10,000$40,10050,000 total
Footnotes (4)
  • [F1]Converted from Canadian exercise price of C$2.60 using an exchange rate of C$1.2908 = US$1.00.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from C$5.16 to C$5.1924, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The weighted average sales price reported above was converted from the Canadian weighted average sales price of C$5.1745 using an exchange rate of C$1.2908 = US$1.00.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from C$5.2979 to C$5.3111, inclusive. The reporting person undertakes to provide to Aptose Biosciences, Inc., any security holder of Aptose Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The weighted average sales price reported above was converted from the Canadian weighted average sales price of C$5.3003 using an exchange rate of C$1.2908 = US$1.00.
  • [F4]The options were granted on 1/2/2019 and fully vested on 1/2/2020.

Documents

1 file

Issuer

Aptose Biosciences Inc.

CIK 0000882361

Entity typeother

Related Parties

1
  • filerCIK 0001761449

Filing Metadata

Form type
4
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 6:00 PM ET
Size
11.6 KB